F-star Therapeutics, Inc. Common Stock
FSTX
FSTX was delisted on the 8th of March, 2023.
28 hedge funds and large institutions have $2.77M invested in F-star Therapeutics, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 5 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
10% less funds holding
Funds holding: 31 → 28 (-3)
50% less capital invested
Capital invested by funds: $5.59M → $2.77M (-$2.82M)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$176K |
| 2 |
ED
Exane Derivatives
Paris,
France
|
+$106K |
| 3 |
JP Morgan Chase
New York
|
+$42K |
| 4 |
Bank of New York Mellon
New York
|
+$38.9K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$33.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$969K |
| 2 |
HP
Hikari Power
Tokyo,
Japan
|
-$207K |
| 3 |
TA
Tiedemann Advisors
New York
|
-$80.2K |
| 4 |
Millennium Management
New York
|
-$54.2K |
| 5 |
AIM
Alambic Investment Management
Belvedere,
California
|
-$16K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | -$233 | -45 | -8% |
|
27
BNP Paribas Financial Markets
Paris,
France
| $72 | – | – | – |
|
|
BBA
28
Baker Bros. Advisors
New York
| – | -$969K | -153,286 | Closed |
|
|
HP
29
Hikari Power
Tokyo,
Japan
| – | -$207K | -32,818 | Closed |
|
|
AIM
30
Alambic Investment Management
Belvedere,
California
| – | -$16K | -2,525 | Closed |
|
31
Wells Fargo
San Francisco,
California
| – | -$5.69K | -1,099 | -98% |
|
|
MAM
32
Meeder Asset Management
Dublin,
Ohio
| – | -$4K | -696 | Closed |
|
FSTX Hedge Fund Activity: Q1 2020 in Review
28 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q1 2020, worth a combined $2.77M — down 50% from $5.59M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of FSTX and 2 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $176K. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $969K sold.
- 28 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q1 2020, down from 31 in Q4 2019.
- Funds reported $2.77M of F-star Therapeutics, Inc. Common Stock stock for Q1 2020, down 50% quarter-over-quarter.
- 2 funds opened new F-star Therapeutics, Inc. Common Stock positions in Q1 2020 and 5 closed out, a net change of -3 holders.
- The largest F-star Therapeutics, Inc. Common Stock buyer in Q1 2020 was Renaissance Technologies, an estimated $176K added.
- The largest F-star Therapeutics, Inc. Common Stock seller in Q1 2020 was Baker Bros. Advisors, an estimated $969K sold.
Based on aggregated 13F filings for Q1 2020.